Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 3:29 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 8,265 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Risk Clear all
Completed Not applicable Interventional Results available

Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign

NCT03068273
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Real-time CGM data
Device
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Nov 2, 2026, 3:29 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Disturbances as a Risk Factor in Chronic Kidney Disease

NCT00817427
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Controls Short sleep, CKD- sleep extension
Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 74 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Nov 2, 2026, 3:29 PM EST
Active, not recruiting Phase 2 Interventional

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373
View directory record Official record
Conditions
Neuroblastoma
Interventions
GM-CSF + Naxitamab
Biological
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
1 Year and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 2, 2026, 3:29 PM EST
Terminated Phase 1 Interventional Results available

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

NCT04751383
View directory record Official record
Conditions
High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, Magnetic Resonance Imaging, Magrolimab, Resection
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 2, 2026, 3:29 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy

NCT01815047
View directory record Official record
Conditions
Inflammation, Infection
Interventions
Vitamin D3 Supplementation
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
13 Years to 18 Years · Female only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Nov 2, 2026, 3:29 PM EST
Terminated Not applicable Interventional Results available

Community Hospital Identification of High CV Risk Patients During Cancer Treatment

NCT02566109
View directory record Official record
Conditions
Breast Cancer
Interventions
Fast MRI
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Nov 2, 2026, 3:29 PM EST
Completed Not applicable Interventional Results available

Broadening the Reach, Impact, and Delivery of Genetic Services

NCT03985852
View directory record Official record
Conditions
Cancer, Risk Reduction Behavior
Interventions
Patient Directed Standard of Care
Other
Lead sponsor
University of Utah
Other
Eligibility
25 Years to 60 Years
Enrollment
3,073 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Nov 2, 2026, 3:29 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides

NCT00728338
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Docosahexenoic acid (DHA), Olive oil
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
39 Years to 66 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2008 · Synced Nov 2, 2026, 3:29 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

GARM II: A Study on the Genetics of Age-related Maculopathy

NCT01115387
View directory record Official record
Conditions
Age-related Macular Degeneration, Age-related Maculopathy
Interventions
Observational-1, Observational-2
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
49 Years and older
Enrollment
603 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Nov 2, 2026, 3:29 PM EST
Not listed Phase 4 Interventional

The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection

NCT02307006
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Ceftaroline, Cefazolin / Vancomycin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Cincinnati, Ohio • West Chester, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Nov 2, 2026, 3:29 PM EST
Completed No phase listed Observational

Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)

NCT00773409
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Not listed
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
Not listed
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Nov 2, 2026, 3:29 PM EST
Completed Phase 2 Interventional Results available

Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer

NCT02353832
View directory record Official record
Conditions
Prostate Cancer
Interventions
Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Nov 2, 2026, 3:29 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Public Health Program to Reduce Risk of Antepartum Depression

NCT02144844
View directory record Official record
Conditions
Depression
Interventions
Insight-Plus Cognitive Behavioral Intervention
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Nov 2, 2026, 3:29 PM EST
Enrolling by invitation No phase listed Observational

Developing Evidence to Inform Regulatory Policy on Nicotine Content in E-Liquids

NCT06619964
View directory record Official record
Conditions
Nicotine Addiction
Interventions
Not listed
Lead sponsor
Rochester Institute of Technology
Other
Eligibility
21 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Nov 2, 2026, 3:29 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Identifying Driving Risk Factors in Type 1 Diabetes and Their Reduction Via Internet Program (DiabetesDriving.Com)

NCT01563887
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
DD.com, DD.com + MI
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
568 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Nov 2, 2026, 3:29 PM EST
Completed Phase 2 Interventional Results available

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

NCT05568706
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
31
States / cities
Tempe, Arizona • Fresno, California • Lomita, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 2, 2026, 3:29 PM EST
Active, not recruiting Not applicable Interventional

Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

NCT04338152
View directory record Official record
Conditions
Psychotic Disorders, Prodromal Symptoms, Prodromal Schizophrenia, Psychosis, Family
Interventions
Family Focused Therapy for Clinical High Risk Youth (FFT-CHR), Enhanced Care (EC)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 25 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Nov 2, 2026, 3:29 PM EST
Completed Not applicable Interventional Results available

Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer

NCT00084552
View directory record Official record
Conditions
Prostate Cancer, Sexual Dysfunction, Sexuality and Reproductive Issues
Interventions
radiation therapy
Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Nov 2, 2026, 3:29 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

On the Move: Optimizing Participation in Group Exercise

NCT01986647
View directory record Official record
Conditions
Physical Disability
Interventions
On the Move exercise - exercise leader, Standard program - exercise leader, On the Move exercise - staff activity personnel, Standard program - staff activity personnel
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Nov 2, 2026, 3:29 PM EST
Completed Not applicable Interventional

DMHI for At-Risk College Students

NCT06608498
View directory record Official record
Conditions
Prodromal Symptoms, Psychosis
Interventions
SPARK Coping
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Nov 2, 2026, 3:29 PM EST
Recruiting Phase 3 Interventional

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

NCT07466316
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Lumbar Puncture, Lymph Node Biopsy, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Resection, Survey Administration, Vincristine Sulfate, Vinorelbine Tartrate
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
86
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 71 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 2, 2026, 3:29 PM EST
Completed Phase 1 Interventional

Cangrelor Neonatal PK/PD and Safety Study

NCT02765633
View directory record Official record
Conditions
Partial Obstruction of Systemic to Pulmonary Artery Shunt, Complete Obstruction of Systemic to Pulmonary Artery Shunt
Interventions
Cangrelor
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
1 Day to 28 Days
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Nov 2, 2026, 3:29 PM EST
Withdrawn No phase listed Observational

Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy

NCT02543957
View directory record Official record
Conditions
Cholangitis, Bacteremia
Interventions
Cholangioscopy
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Nov 2, 2026, 3:29 PM EST
Completed Phase 2 Interventional

Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer

NCT00349557
View directory record Official record
Conditions
Prostate Cancer
Interventions
bevacizumab, bicalutamide and goserelin, intensity modulated radiation therapy (IMRT)
Drug · Procedure
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Nov 2, 2026, 3:29 PM EST